clinical trials with apsac , still ongoing , allow the following tentative conclusions : the efficacy of intravenous apsac appears to be equivalent to that of intracoronary streptokinase , when given within 4 hours of the onset of symptoms of myocardial infarction , and superior to that of intravenous streptokinase , but it is easier to administer .
C0027051
myocardial
C0038418
streptokinase